Calcium channel blockers in the treatment of hypertension

Calcium channel blockers [CCBs] have gained increasing importance in the treatment of hypertension during recent years. These drugs lower the blood pressure by their cardiac and vascular effects. Possible cardio protection and a favorable influence on progression of atherosclerosis may be the additional advantages. Some aspects of basic and clinical pharmacology of CCBs are reviewed in this article

Prostaglandin E1: a new approach for the treatment of occlusive arterial disease

Prostaglandin El [PGE1], an eicosanoid, has a favourable profile of actions in occlusive arterial disease after intra-arterial and intravenous administration. It causes vasodilatation, increases peripheral blood flow, inhibits platelet activation, improves RBC deformability, increases fibroblast fibrinolytic activity and reduces atherogenesis. PGE1 used in the treatment of occlusive arterial disease reduces the resting ischaemic pain, promotes healing of trophic lesions and may avoid the threatening amputation